PMID- 20889923
OWN - NLM
STAT- MEDLINE
DCOM- 20110414
LR  - 20210206
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 117
IP  - 3
DP  - 2011 Jan 20
TI  - Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in 
      haploidentical hematopoietic stem cell transplantation.
PG  - 764-71
LID - 10.1182/blood-2010-08-264085 [doi]
AB  - Natural killer (NK) cells are key members of the innate immune system. In a 
      self-environment, they sense and kill target cells lacking major 
      histocompatibility complex class I molecules and release various cytokines on 
      activation. The discovery of human leukocyte antigen (HLA) class I specific 
      inhibitory receptors (including the allotype-specific killer immunoglobulin-like 
      receptors), and of various activating receptors and their ligands, provided the 
      basis for understanding the molecular mechanism of NK-cell activation and 
      function, mainly resulting from the balance between activating and inhibitory 
      signals. In an allogeneic setting, such as T cell-depleted haploidentical 
      hematopoietic stem cell transplantation, NK cells may express inhibitory killer 
      immunoglobulin-like receptors that are not engaged by any of the HLA class I 
      alleles present on allogeneic cells. Such "alloreactive" NK cells greatly 
      contribute both to eradication of leukemia blasts escaping the preparative 
      regimen and to clearance of residual host dendritic cells and T lymphocytes (thus 
      preventing graft-versus-host disease and graft rejection, respectively). Improved 
      prevention of graft-versus-host disease might be achieved by redirecting to lymph 
      nodes adoptively transferred, alloreactive NK cells by inducing CCR7-uptake in 
      vitro. Recent studies suggested that, after immune-suppressive therapy, 
      alloreactive NK cells from an HLA-haploidentical donor may prevent leukemia 
      recurrence also in patients who have not received allogeneic hematopoietic stem 
      cell transplantation.
FAU - Moretta, Lorenzo
AU  - Moretta L
AD  - Giannina Gaslini Institute, Genova-Quarto, Italy. 
      lorenzomoretta@ospedale-gaslini.ge.it
FAU - Locatelli, Franco
AU  - Locatelli F
FAU - Pende, Daniela
AU  - Pende D
FAU - Marcenaro, Emanuela
AU  - Marcenaro E
FAU - Mingari, Maria Cristina
AU  - Mingari MC
FAU - Moretta, Alessandro
AU  - Moretta A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20101001
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Graft Rejection/immunology
MH  - Graft vs Host Disease/immunology
MH  - HLA Antigens/immunology/metabolism
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Killer Cells, Natural/*immunology/metabolism
MH  - Models, Immunological
MH  - Receptors, CCR7/immunology/metabolism
MH  - Receptors, KIR/*immunology/metabolism
EDAT- 2010/10/05 06:00
MHDA- 2011/04/16 06:00
CRDT- 2010/10/05 06:00
PHST- 2010/10/05 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2011/04/16 06:00 [medline]
AID - S0006-4971(20)59655-9 [pii]
AID - 10.1182/blood-2010-08-264085 [doi]
PST - ppublish
SO  - Blood. 2011 Jan 20;117(3):764-71. doi: 10.1182/blood-2010-08-264085. Epub 2010 
      Oct 1.